Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 1142524 in type 2 diabetes mellitus with diabetic kidney disease
MOH_2018-03-08_000834Phase 2Completed
- Sponsor
- Bayer
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic glomerulosclerosis comparing BAY 1142524 + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Primary efficacy assessment. Started Nov 2017; status: completed.
02
Drugs
fulacimstat
03
Conditions
diabetic glomerulosclerosis
Beyond the preview
Go deeper on MOH_2018-03-08_000834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-03-08_000834.